SummaryRMgm-787
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 23028336 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943) |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | D.S. Guttery; R. Tewari |
Name Group/Department | Centre for Genetics and Genomics, School of Biology, Queens Medical Centre |
Name Institute | University of Nottingham |
City | Nottingham |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-787 |
Principal name | ppkl- cl3; ppkl- cl9 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal gametocyte production. Normal gamete formation (exflagellation). Aberrant development of ookinetes. Development of the zygote through stages I–III of ookinete maturity (0–9 h post-fertilisation)was indistinguishable in the ppkl- mutants compared to wild-type. Wild-type controls showed normal progression and maturation to stage IV (at 12 h), with 69% of all macrogamete-derived parasites progressing to stage VI 24 h post-fertilisation. In contrast, the majority of ppkl2 mutants did not progress from stage III to stage IV, but produced a high proportion of abnormal retort forms 24 h post fertilisation (35% of the total population) with only 4% progressing to stage IV–VI. Ookinetes are affected in motility and migration through the midgut wall |
Oocyst | No oocyst formation. Ookinetes are affected in motility and migration through the midgut wall |
Sporozoite | No oocyst formation and not sporozoite formation |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Protein (function) Phenotype Whether the observed defect was sex-specific was examined by performing genetic crosses between ppkl- parasites and lines deficient in either male (map2-) or female (nek4-) gametes. Cross-fertilization with nek4- parasites did not rescue the phenotype, whereas crossing with map2- gametocytes resulted in 26% of all macrogamete-derived parasites progressing to stage VI, revealing that the requirement for the phosphatase is inherited through the female line. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1329500 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1466100 | ||||||||||||||||||||||||
Gene product | protein phosphatase containing kelch-like domains | ||||||||||||||||||||||||
Gene product: Alternative name | PPKL; PPalpha; PfPPα | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | ApaI, XbaI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The targeting vector for ppkl was constructed using the pBSDHFR plasmid, which contains polylinker sites flanking a Toxoplasma gondii dhfr/ts expression cassette conveying resistance to pyrimethamine. PCR primers P0011P (5'-CCCCGGGCCCCATGTTTTATATTGTGTTTTGGC-3') and P0012P (5'-GGGGAAGCTTCAAACATTCGTTTCTTTAAATGATCC-3') were used to generate a 788 bp fragment of 5' upstream sequence of ppkl from genomic DNA, which was inserted into ApaI and HindIII restriction sites upstream of the dhfr/ts cassette of pBS-DHFR. A 694 bp fragment generated with primers P0013P (5'-CCCCGAATTCCCACCAACCCCACCAAGAAGTCAACCG-3') and P0014P (5'-GGGGTCTAGACCGGCAAATTGATGAAATCGC-3') from the 3' flanking region of ppkl was then inserted downstream of the dhfr/ts cassette using EcoRI and XbaI restriction sites. The linear targeting sequence was released using ApaI/XbaI. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |